MX2020007860A - Tratamientos combinados para crisis de opioides. - Google Patents

Tratamientos combinados para crisis de opioides.

Info

Publication number
MX2020007860A
MX2020007860A MX2020007860A MX2020007860A MX2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A
Authority
MX
Mexico
Prior art keywords
opioid
effective amount
alcohol
medication
death
Prior art date
Application number
MX2020007860A
Other languages
English (en)
Inventor
Michael Presti
Original Assignee
Michael Presti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Presti filed Critical Michael Presti
Publication of MX2020007860A publication Critical patent/MX2020007860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para reducir el riesgo de sobredosis relacionada con la medicación, muerte u otra lesión asociada con el consumo inapropiado de alcohol junto con analgésicos opioides de prescripción, que comprende: administrar un medicamento combinado que tenga una cantidad efectiva de uno o más medicamentos opioides y un cantidad de uno o más inhibidores de la aldehído deshidrogenasa, con el fin de proporcionar los poderosos efectos analgésicos del opioide junto con una sustancia que previene el consumo concomitante de alcohol, reduciendo así el riesgo de sobredosis de opioides mediada por alcohol o la muerte. Un medicamento combinado, que incluye una cantidad efectiva de uno o más medicamentos opioides, y una cantidad efectiva de uno o más inhibidores de la aldehido deshidrogenasa y un vehículo farmacéuticamente aceptable.
MX2020007860A 2018-01-26 2019-01-23 Tratamientos combinados para crisis de opioides. MX2020007860A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/881,475 US10478408B2 (en) 2018-01-26 2018-01-26 Combination treatments for opioid crisis
PCT/US2019/014659 WO2019147606A1 (en) 2018-01-26 2019-01-23 Combination treatments for opioid crisis

Publications (1)

Publication Number Publication Date
MX2020007860A true MX2020007860A (es) 2020-09-03

Family

ID=67392667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007860A MX2020007860A (es) 2018-01-26 2019-01-23 Tratamientos combinados para crisis de opioides.

Country Status (5)

Country Link
US (3) US10478408B2 (es)
EP (1) EP3743073A4 (es)
CA (1) CA3089071A1 (es)
MX (1) MX2020007860A (es)
WO (1) WO2019147606A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478408B2 (en) 2018-01-26 2019-11-19 Michael Presti Combination treatments for opioid crisis
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023177841A2 (en) * 2022-03-18 2023-09-21 Presti Michael Combination products to mitigate misuse of central nervous system stimulants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140032A (en) * 1990-10-01 1992-08-18 Radecki Thomas E Drug therapy for alcohol abusers
CA2414500A1 (en) 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
US8791093B2 (en) 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
US10478408B2 (en) 2018-01-26 2019-11-19 Michael Presti Combination treatments for opioid crisis

Also Published As

Publication number Publication date
US10478408B2 (en) 2019-11-19
CA3089071A1 (en) 2019-08-01
US20210161835A1 (en) 2021-06-03
US10881625B2 (en) 2021-01-05
US20190231719A1 (en) 2019-08-01
US20200038346A1 (en) 2020-02-06
US11786490B2 (en) 2023-10-17
US20220000809A1 (en) 2022-01-06
EP3743073A4 (en) 2021-11-03
EP3743073A1 (en) 2020-12-02
WO2019147606A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2020007860A (es) Tratamientos combinados para crisis de opioides.
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
NZ700623A (en) Botulinum toxin dosage regimen for chronic migraine prophylaxis
WO2008064192A3 (en) Modified release analgesic suspensions
MX343867B (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
MX2021008247A (es) Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
AR052880A1 (es) Metodo para tratar dolor visceral
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
IS2630B (is) Meðferð á fráhvarfseinkennum
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
MX359672B (es) Metodo para manejo de dolor cronico y tratamiento usando hcg.
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
Chotton et al. The effect of pregabalin for relief of postoperative pain after abdominal hysterectomy
AU2018269678A1 (en) FLT3 inhibitors for improving pain treatments by opioids
Konuganti et al. Pre-emptive 8 mg dexamethasone and 120 mg etoricoxib for pain prevention after periodontal surgery: a randomised controlled clinical trial
TW201642906A (en) Fixed dose combination for pain relief without edema
McKellar et al. Update on the use of analgesics versus nonsteroidal anti-inflammatory drugs in rheumatic disorders: risks and benefits
CL2011002863A1 (es) Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral.
IN2014DN06117A (es)
WO2016077565A3 (en) Methods for chronic pain management and treatment using hcg
Butenko et al. “Pharmaceutical addiction”–consequences of alternative application of medicines
MX357376B (es) Composicion farmaceutica para uso en inflamacion y dolor.
Stevens et al. A Retrospective Analysis of the Effects of Transversus Abdominis Plane Blocks With and Without Analgesic Ketamine in Multimodal Analgesia Regimens for Total Abdominal Hysterectomy Surgery
NZ724912A (en) Transmucosal drug delivery devices for use in chronic pain relief